Search | Clinical Trials Finder

Conditions: Dry Eye
Interventions: DE-110 ophthalmic suspension high dose, DE-110 ophthalmic suspension low dose, Placebo; Drug · Other
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Inglewood, California • Newport Beach, California • Petaluma, California + 11 more

Conditions: Actinic Keratoses
Interventions: imiquimod cream, 3.75%, Vehicle Cream; Drug
Lead sponsor: Actavis Mid-Atlantic LLC; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 19
States / cities: Birmingham, Alabama • Miami, Florida • Newnan, Georgia + 16 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Placebo (0.5ml), Placebo (1.0ml), Grass MATA MPL (0.5ml) 5100SU, Grass MATA MPL (1.0ml) 10200SU, Grass MATA MPL (1.0ml) 18200SU, Grass MATA (0.5ml) 5100SU; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Acute Coronary Syndrome
Interventions: Ticagrelor, Clopidogrel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 18,624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 139
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 136 more

Conditions: Respiratory Distress Syndrome
Interventions: Not listed
Lead sponsor: Children's Hospitals and Clinics of Minnesota; Other
Eligibility: 1 Day to 30 Days
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy, Renal Insufficiency
Interventions: LY3437943; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Tustin, California • Miami, Florida • Orlando, Florida + 1 more

Conditions: Healthy
Interventions: RO7239361; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cypress, California

Conditions: Parkinson Disease
Interventions: Location of Visit; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 45 Years to 90 Years
Enrollment: 30 participants
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Asthma
Interventions: Salbutamol HFA-134a, Salbutamol HFA-152a; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 37
States / cities: North Hollywood, California • San Mateo, California • Aventura, Florida + 32 more

Conditions: COPD
Interventions: BGF MDI 320/14.4/9.6 μg, GFF MDI (PT003) 14.4/9.6 μg, BFF MDI (PT009) 320/9.6 μg, Symbicort® Turbuhaler® (TBH) Inhalation Powder; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 63
States / cities: Andalusia, Alabama • Jasper, Alabama • Peoria, Arizona + 54 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Propionate/Salmeterol Combination Product, Salmeterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 95
States / cities: Jasper, Alabama • Mobile, Alabama • Glendale, Arizona + 88 more

Conditions: Diastasis Recti and Weakness of the Linea Alba
Interventions: Exercise; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Plaque Psoriasis
Interventions: Etanercept, CHS-0214; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 50
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 43 more

Conditions: Healthy Volunteer
Interventions: inclacumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Alzheimer's Disease
Interventions: PF-04447943, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 22
States / cities: Northport, Alabama • Costa Mesa, California • Glendale, California + 18 more

Conditions: Proctitis, Ulcerative
Interventions: MAX-002, Placebo, Canasa®; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 22
States / cities: Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 19 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 41
States / cities: Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more

Conditions: Renal Impairment
Interventions: ISIS 681257; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Conditions: Progressive Multiple Sclerosis, Fatigue
Interventions: N-acetyl cysteine, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Colonoscopy
Interventions: Remimazolam, Midazolam, Placebo; Drug
Lead sponsor: Paion UK Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 13
States / cities: Mobile, Alabama • Anaheim, California • Chula Vista, California + 10 more

Conditions: Rheumatoid Arthritis
Interventions: GP2015; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 26
States / cities: Peoria, Arizona • Phoenix, Arizona • El Cajon, California + 21 more

Conditions: Type 2 Diabetes
Interventions: Bydureon, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 29
States / cities: Anaheim, California • Chino, California • Los Angeles, California + 26 more

Conditions: Ocular Infection
Interventions: DCN01, Unisol; Drug
Lead sponsor: Deacon Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Anaemia
Interventions: Daprodustat (GSK1278863), Placebo, Iron therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 49
States / cities: Homewood, Alabama • Little Rock, Arkansas • Downey, California + 44 more

Search by objective public record fields.

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses

Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

Verification of Pulse Oximetry in Neonatal Population

A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function

Compare Bioavailability of RO7239361 After Subcutaneous Injection

Comparison of Health Care Delivery Methods in Parkinson's Disease

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

Impact of Exercise on Diastasis Rectus Abdominus

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)

A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

A Study of Oxidative Pathways in MS Fatigue

A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients

Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis

Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.

A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers

Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)